# Mobilizing KOLs and Reference Sites
A cardiac stent maker walks into three university hospitals with nothing but early clinical data and a hypothesis. Eighteen months later, interventional cardiologists from those same centers are presenting at TCT (Transcatheter Cardiovascular Therapeutics, the field's biggest annual conference), publishing in peer-reviewed journals, and taking calls from peers who want to know: "Should we switch?"
That transformation is not luck. It is a deliberate marketing play built on two assets: KOLs (Key Opinion Leaders, the physicians whose judgment other physicians trust) and reference sites (flagship hospitals whose adoption signals safety to everyone watching).
In biotech and medtech, buyers do not trust your ad. They trust their peers. Your job is to build the peer proof.
Clinicians are trained to be skeptical. A new device or therapy carries real risk: patient harm, malpractice exposure, and reputational damage if it fails. So doctors look for social proofsocial proofThe tendency of people to look at others' choices to guide their own. In marketing, it means using reviews, testimonials, ratings and case studies to reassure and persuade prospects.Voir la définition complète → before they change practice.
Answer both credibly and you de-risk the decision for the cautious majority (the "followers"). This maps neatly onto the classic adoption curve from Everett Rogers's Diffusion of Innovations. KOLs are your innovators and early adopters. Their published, spoken endorsement is what pulls the early majority across the chasm.
One key rule up front: KOL engagement is heavily regulated. In the US, the Sunshine Act (part of the Affordable Care Act) requires manufacturers to publicly report payments to physicians via Open Payments. Every honorarium, meal, and consulting fee is disclosed. Marketing and compliance are joined at the hip here. Never treat a KOL relationship as a way to "buy" a prescription or an implant decision. That is illegal and it destroys credibility.
Before you recruit anyone, you need a mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.Voir la définition complète →. Not just "who is famous," but who actually moves opinion in your specific therapeutic area.
Build a KOL mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.Voir la définition complète → across a few dimensions:
Tiering helps. A common approach:
Do not over-index on Tier 1. Rising stars are frequently your best early partners: energetic, less booked, and eager to build a name through your data.
Tools exist for this (Veeva, H1, and similar platforms mine publications, trials, and claims data), but a diligent analyst with PubMed, conference agendas, and Open Payments can build a strong first mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.Voir la définition complète → for a narrow specialty.
The rookie mistake is leading with a consulting fee. KOLs who matter are motivated by something else: advancing the science, building their own reputation, and improving patient outcomes.
Recruit by offering a genuine platform:
For our stent maker, the pitch to the three academic centers was not "we will pay you." It was "we will give you early access to the device and the data, support a rigorous evaluation, and help you publish and present what you find, good or bad."
That last phrase matters. Credibility requires that the KOL is free to report honestly. A KOL who only ever says glowing things gets discounted by peers immediately.
🎬 [VIDEO: "How Pharma and Medtech Work With Key Opinion Leaders" — youtube.com — a plain-language overview of KOL engagement models and compliance guardrails]
A KOL is a person. A reference site is an institution that has operationalized your product. The distinction matters because followers ask a different question: "Can a serious hospital actually run this at scale, in their workflow, with their staff?"
Turning an account into a reference site means:
The stent maker built its three academic centers into exactly this: places a skeptical community hospital could visit, watch a live case, and ask the cath lab team blunt questions about complications and workflow.
A reference site is a marketing asset you co-create over months. Treat it like a partnership with a service-level commitment on your side: fast support, on-site training, rapid issue resolution. A reference site that feels neglected becomes a reference against you.
Timing is everything. Activating KOLs before you have data, or dumping all your evidence at once, wastes the asset. Sequence it.
A workable sequence:
1. Evidence first. Get clinical data (or strong real-world evidence) that a KOL can stand behind. No data, no credible advocacy.
2. Engage Tier 1 quietly as advisors and investigators. Their early involvement gives the program legitimacy.
3. Build reference sites in parallel so there is something to point to.
4. Publish. Peer-reviewed papers are the durable currency. They outlast any single conference.
5. Take the podium. Time major presentations to flagship conferences (TCT, ACC, ESC in cardiology) to maximize reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.Voir la définition complète →.
6. Cascade to Tier 2 and Tier 3, using the Tier 1 evidence and reference sites as proof for the followers.
The logic: each layer de-risks the next. National KOLs and publications de-risk regional adoption. Reference sites de-risk the individual hospital's operational fear. By the time your sales team calls the early majority, the peer proof is already built.
Vérification des acquis
1. Why do KOLs and reference sites play such a decisive role in driving adoption of new medtech and biotech products?
2. In the context of Rogers's Diffusion of Innovations, what role do KOLs primarily play in the adoption process?
3. A medtech firm has strong endorsements from individual star physicians but no flagship hospital has formally committed to its device. Which adoption question remains unanswered for cautious buyers?
4. Select ALL correct answers about why manufacturers must approach KOL engagement carefully in the US.
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers describing what genuine 'peer proof' provides to the cautious majority of clinicians.
Sélectionnez toutes les réponses correctes.
Buying voices instead of building them. Payments create disclosure obligations and skepticism, not conviction. Peers can see Open Payments data.
One-way relationships. If you only call KOLs when you need a favor, engagement decays. Sustained value (data, research, platform) keeps it alive.
Ignoring the "detractor KOL." The influential skeptic will not disappear. Engage them directly, share your data, and take their objections seriously. Converting or neutralizing a respected skeptic is often worth more than adding another supporter.
Reference sites with no proof. A flagship logo means nothing if the site cannot show outcomes or will not host a peer visit. Enthusiasm is not evidence.
Compliance as an afterthought. In regulated markets, marketing and medical/compliance teams must co-own KOL programs. Off-label promotion (promoting uses your product is not approved for) and undisclosed payments carry serious legal risk. Coordinate early and document everything.
Track leading and lagging indicators:
The clean test: when a follower says "I want to talk to the team at [reference site] before we decide," your program is working. You have made your marketing invisible by making the peer proof visible.